Supplementary Figures and Table from Targeted Therapy Given after Anti–PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity

Abstract
S1: IT monotherapy in SW1 model S2: IT->dabrafenib-trametinib therapy in BRAF mutant melanoma. S3: IT->TT sequence in NRAS#5 model S4: Expanded heatmap of all immune cells S5: IT->TT increases accumulation of activated CD8+ T cells S6: The TT->IT sequence on T cells, Tregs and MDSCS S7: Expanded heatmap of T and NK cells S8: IT->TT increases accumulation of activated CD8+ T cells, pathway analysis. S9: Expanded heatmap of myeloid cell data S10: IT->TT sequence increases expression of MHC I mRNAs S11: TT affects melanoma antigens S12: IC50 curves showing resistance to TT S13: Model showing mechanism of IT->TT sequence ST1: tumor weights at the end of the experiment